Meanwhile, the company s earnings before interest, taxes, depreciation and amortization (EBITDA) came in at Rs 320.5 crore, up from Rs 297 crore in the year-ago period.
Even as Motilal Oswal Securities has upped its target price for Gland Pharma to Rs 1,560, it was short of Rs 1,612.60, the level drug maker settled at on Tuesday.
Stocks that were in action included names like Gland Pharma, which was up 20%, Caplin Point Laboratories, which gained 11%, and HUDCO, which was up more than 6% to hit a fresh 52-week high on Tuesday.